Featuring news, events and industry trends
Teladoc Health Is Providing Free Virtual Health Care Services to Those Impacted by Kentucky Tornadoes

Purchase-headquartered Teladoc Health, the global leader in whole-person virtual care, is providing free, 24/7 general medical telehealth visits to residents, first responders and others directly impacted by the devastating tornadoes in Kentucky. Individuals who are now being displaced can seek treatment from a licensed health care professional for any non-emergency illness by calling Teladoc directly at 855-225-5032.

Earlier this year, Teladoc Health made these virtual care services available at no cost to states in the southern U.S. affected by Hurricane Ida as well as communities dealing with winter storms in Oklahoma and Texas.

For more information, visit https://www.teladoc.com/disaster-hotline/.
Fareri Associates Announces $3 million Grant from Empire State Development

Fareri Associates is in the final approval stages for the North 80 development project, a 1.2-million-square-foot science and technology center. Situated on 80 acres in Mount Pleasant, the project sits adjacent to Westchester Medical Center and New York Medical College, and bears proximity to Regeneron Pharmaceuticals, the nation’s fastest-growing biotech company.

The project will enhance the Hudson Valley’s growing reputation as the leading bioscience and medical technology hub in New York State and the Northeast and will contribute to Westchester’s thriving biotech and healthcare sectors. The innovative science and lifestyle campus is composed of a pedestrian-friendly Main Street lined with shops, a hotel and conference center, restaurants, and landscaped plazas.

The $3 million award to the development was among 97 projects in the state receiving $81 million in Empire State Development funds. The awards were provided through the Regional Economic Development Council initiative and were announced November 22 by Governor Kathy Hochul.
Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for Advanced Cutaneous Melanoma

Sapience Therapeutics, Inc., a biotechnology company in Harrison focused on the discovery and development of peptide therapeutics to address difficult-to-treat cancers, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its lead program, investigating ST101 for the treatment of advanced cutaneous melanoma in patients who have disease progression on or after anti-PD-1/anti-PD-L1 therapy. This is the second FTD designation received for the ST101 program, following FTD for recurrent glioblastoma (GBM), announced in early December 2021. ST101 is currently being evaluated in an ongoing Phase 1-2 clinical study in patients with advanced unresectable and metastatic solid tumors, which includes expansion cohorts in patients with cutaneous melanoma and refractory GBM.
Momentive Performance Materials Releases Sustainability Report

With presence in Tarrytown, Momentive Performance Materials Inc. (Momentive) recently released its 2020-2021 Sustainability Report, which details the company's progress toward achieving 2025 Sustainability Goals, along with its continued focus on integrating sustainability practices into the company-wide culture so to best support customers and stakeholders.

The Report is an overview of the company's sustainability journey, building on the Global Reporting Initiative alignment in Momentive's 2019 Sustainability Report and the Environmental, Social & Corporate Governance Commitment released in June. It also serves as the company's first United Nations Global Compact communication on progress.

To read Momentive's full Sustainability Report and learn more about Sustainability at Momentive, visit Momentive's Sustainability Report | Momentive.
Positive Phase 3 Dupixent® (dupilumab) Data in Children 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis Featured in RAD 2021 Late-Breaking Session

These results will form the basis of global regulatory submissions for this age group, beginning with the U.S. in 2021 and European Union in the first half of 2022.
Call for Applications – 2022-2023 Montefiore Einstein Innovation Biodesign Training Program
The Montefiore Einstein Innovation Leadership Team is excited to announce a call for applications for the Innovation Biodesign Training Program’s 2022-2023 cycle. This one-year program is a unique experience to train the next generation of physician innovators and encourages the development and validation of digital health technologies. This initiative is only the sixth Innovation Biodesign Training Program in the U.S. and the first to focus on chronic conditions and health disparities. Attending physicians and residents and fellows in the research training year(s) are encouraged to apply. Training will begin on July 1, 2022. 
This program’s curriculum (3-4 hours required per week) includes:

  • Health Technology Innovation seminar series and small group sessions;

  • a mentored health technology-oriented project through the innovation biodesign approach; and,

  • mentoring from Montefiore Einstein faculty and external experts.
For more information, visit the program’s website.
To indicate your interest in applying and to request the application packet, please e-mail Dr. Jariwala (sjariwal@montefiore.org). The application deadline is February 1, 2022.

Have good news to share from
Westchester’s biosciences ecosystem?

Please let us know.

If you would like to continue receiving this weekly newsletter,
please sign up below. If you would like to contact us directly, click the Contact Us link.